IBDEI0DB ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6355,1,5,0)
 ;;=5^250.01
 ;;^UTILITY(U,$J,358.3,6355,2)
 ;;=^331780
 ;;^UTILITY(U,$J,358.3,6356,0)
 ;;=250.11^^44^511^3
 ;;^UTILITY(U,$J,358.3,6356,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6356,1,4,0)
 ;;=4^DMI w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,6356,1,5,0)
 ;;=5^250.11
 ;;^UTILITY(U,$J,358.3,6356,2)
 ;;=^331784
 ;;^UTILITY(U,$J,358.3,6357,0)
 ;;=250.21^^44^511^2
 ;;^UTILITY(U,$J,358.3,6357,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6357,1,4,0)
 ;;=4^DMI w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,6357,1,5,0)
 ;;=5^250.21
 ;;^UTILITY(U,$J,358.3,6357,2)
 ;;=^331788
 ;;^UTILITY(U,$J,358.3,6358,0)
 ;;=250.41^^44^511^5
 ;;^UTILITY(U,$J,358.3,6358,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6358,1,4,0)
 ;;=4^DMI w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,6358,1,5,0)
 ;;=5^250.41
 ;;^UTILITY(U,$J,358.3,6358,2)
 ;;=^331796
 ;;^UTILITY(U,$J,358.3,6359,0)
 ;;=250.51^^44^511^1
 ;;^UTILITY(U,$J,358.3,6359,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6359,1,4,0)
 ;;=4^DMI w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,6359,1,5,0)
 ;;=5^250.51
 ;;^UTILITY(U,$J,358.3,6359,2)
 ;;=^331800
 ;;^UTILITY(U,$J,358.3,6360,0)
 ;;=250.61^^44^511^4
 ;;^UTILITY(U,$J,358.3,6360,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6360,1,4,0)
 ;;=4^DMI w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,6360,1,5,0)
 ;;=5^250.61
 ;;^UTILITY(U,$J,358.3,6360,2)
 ;;=^331804
 ;;^UTILITY(U,$J,358.3,6361,0)
 ;;=250.71^^44^511^6
 ;;^UTILITY(U,$J,358.3,6361,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6361,1,4,0)
 ;;=4^DMI w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,6361,1,5,0)
 ;;=5^250.71
 ;;^UTILITY(U,$J,358.3,6361,2)
 ;;=^331808
 ;;^UTILITY(U,$J,358.3,6362,0)
 ;;=250.00^^44^511^14
 ;;^UTILITY(U,$J,358.3,6362,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6362,1,4,0)
 ;;=4^DMII w/o COMPLICATIONS
 ;;^UTILITY(U,$J,358.3,6362,1,5,0)
 ;;=5^250.00
 ;;^UTILITY(U,$J,358.3,6362,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,6363,0)
 ;;=250.10^^44^511^10
 ;;^UTILITY(U,$J,358.3,6363,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6363,1,4,0)
 ;;=4^DMII w/ KETOACIDOSIS
 ;;^UTILITY(U,$J,358.3,6363,1,5,0)
 ;;=5^250.10
 ;;^UTILITY(U,$J,358.3,6363,2)
 ;;=^331783
 ;;^UTILITY(U,$J,358.3,6364,0)
 ;;=250.20^^44^511^9
 ;;^UTILITY(U,$J,358.3,6364,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6364,1,4,0)
 ;;=4^DMII w/ HYPEROSMOLARITY
 ;;^UTILITY(U,$J,358.3,6364,1,5,0)
 ;;=5^250.20
 ;;^UTILITY(U,$J,358.3,6364,2)
 ;;=^331787
 ;;^UTILITY(U,$J,358.3,6365,0)
 ;;=250.40^^44^511^12
 ;;^UTILITY(U,$J,358.3,6365,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6365,1,4,0)
 ;;=4^DMII w/ RENAL COMPL
 ;;^UTILITY(U,$J,358.3,6365,1,5,0)
 ;;=5^250.40
 ;;^UTILITY(U,$J,358.3,6365,2)
 ;;=^331795
 ;;^UTILITY(U,$J,358.3,6366,0)
 ;;=250.50^^44^511^8
 ;;^UTILITY(U,$J,358.3,6366,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6366,1,4,0)
 ;;=4^DMII w/ EYE COMPL
 ;;^UTILITY(U,$J,358.3,6366,1,5,0)
 ;;=5^250.50
 ;;^UTILITY(U,$J,358.3,6366,2)
 ;;=^331799
 ;;^UTILITY(U,$J,358.3,6367,0)
 ;;=250.60^^44^511^11
 ;;^UTILITY(U,$J,358.3,6367,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6367,1,4,0)
 ;;=4^DMII w/ NEUROLOGICAL COMPL
 ;;^UTILITY(U,$J,358.3,6367,1,5,0)
 ;;=5^250.60
 ;;^UTILITY(U,$J,358.3,6367,2)
 ;;=^331803
 ;;^UTILITY(U,$J,358.3,6368,0)
 ;;=250.70^^44^511^13
 ;;^UTILITY(U,$J,358.3,6368,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6368,1,4,0)
 ;;=4^DMII w/ VASCULAR COMPL
 ;;^UTILITY(U,$J,358.3,6368,1,5,0)
 ;;=5^250.70
 ;;^UTILITY(U,$J,358.3,6368,2)
 ;;=^331807
 ;;^UTILITY(U,$J,358.3,6369,0)
 ;;=251.0^^44^511^16
 ;;^UTILITY(U,$J,358.3,6369,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6369,1,4,0)
 ;;=4^HYPOGLYCEMIC COMA
